Skip to content

Beware of Scam Using Our Company Name for Fake Job Interviews

Beware of Scam Using Our Company Name for Fake Job Interviews

Beware of Scam Using Our Company Name for Fake Job Interviews

Beware of Scam Using Our Company Name for Fake Job Interviews

Dear Valued Partners and Friends,

We hope this message finds you well. We have recently become aware of a scam involving Scailyte’s name and information, which we feel is crucial to bring to your attention.

The scammers are using our brand name to trick people into downloading a chat app with the promise of a job interview. They impersonate our HR representatives and engage in fake interviews, often asking for sensitive personal information or money in the name of a job offer.

Please be aware that we have not authorized any third-party apps or services to conduct job interviews on our behalf. All our official job postings can be found on our website, and we only use authorized communication channels for our recruitment process.

To protect yourself from this scam, please follow these guidelines:

  1. Always verify the source of any job offers or interview invitations, and ensure they come directly from our official channels.

  2. Never download any unknown apps or software, particularly if you receive unsolicited requests to do so.

  3. Never provide personal or financial information to anyone claiming to represent our company without verifying their identity.

  4. If you encounter any suspicious activities, please report them to us immediately at contact@scailyte.com.

Report your fraud, scams and bad business practices at https://reportfraud.ftc.gov/

We apologize for any confusion or inconvenience this may have caused and thank you for your continued trust in our brand. We are working closely with the appropriate authorities to address this.

Best regards,

Peter Nestorov, CEO

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

ISCT 2023

Diana Stoycheva and Filipa Teixeira will be attending the ISCT 2023 Annual Meeting from 31st May to ...

Read more

Recent News

Future Labs Live 2023

Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...

Read more

Recent News

The psychological and economic impact of endometriosis

We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...

Read more

Recent News

Jan Lichtenberg joins Scailyte's Board of Directors

Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...

Read more

Recent News

Challenges and opportunities for innovation in Endometriosis

Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...

Read more

Recent News

Swiss Biotech Day 2023

Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...

Read more

Recent News

Deciphering Disease Mechanisms Through Functional Genomics

Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...

Read more

Recent News

Women's Health Innovation Summit

Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...

Read more

Recent News

01 /04

ISCT 2023

Diana Stoycheva and Filipa Teixeira will be attending the ISCT 2023 Annual Meeting from 31st May to ...

Read more

Future Labs Live 2023

Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...

Read more

Recent News

02 /04

The psychological and economic impact of endometriosis

We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...

Read more

Jan Lichtenberg joins Scailyte's Board of Directors

Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...

Read more

Recent News

03 /04

Challenges and opportunities for innovation in Endometriosis

Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...

Read more

Swiss Biotech Day 2023

Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...

Read more

Recent News

04 /04

Deciphering Disease Mechanisms Through Functional Genomics

Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...

Read more

Women's Health Innovation Summit

Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...

Read more

Recent News